Rxcurve
HCPCS J0589 · per 1 UNIT

Inj daxibotulinumtoxina-lanm

Products billed under this code include Daxxify.

Payment limit per 1 UNIT, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J0589

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Daxxify Revance Therapeutics, Inc. 72960-0112-01 100 $325.20

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $3.252 +$0.185 1 UNIT Inj daxibotulinumtoxina-lanm v1, posted September 17, 2026
3Q26 $3.067 −$0.026 1 UNIT Inj daxibotulinumtoxina-lanm v1, posted September 15, 2026
2Q26 $3.093 −$0.021 1 UNIT Inj daxibotulinumtoxina-lanm v1, posted September 15, 2026
1Q26 $3.114 −$0.034 1 UNIT Inj daxibotulinumtoxina-lanm v1, posted September 15, 2026
4Q25 $3.148 +$0.039 1 UNIT Inj daxibotulinumtoxina-lanm v1, posted September 8, 2026
3Q25 $3.109 +$0.117 1 UNIT Inj daxibotulinumtoxina-lanm v1, posted March 10, 2026
2Q25 $2.992 – 1 UNIT Inj daxibotulinumtoxina-lanm v1, posted March 10, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files